TOWER TRUST & INVESTMENT Co Purchases 891 Shares of Eli Lilly and Company $LLY

TOWER TRUST & INVESTMENT Co increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 891.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 991 shares of the company’s stock after acquiring an additional 891 shares during the quarter. TOWER TRUST & INVESTMENT Co’s holdings in Eli Lilly and Company were worth $1,065,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares in the last quarter. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Finally, 10Elms LLP raised its stake in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Monday. Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Finally, Barclays assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,222.22.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval and commercial setup: Lilly secured approval for its oral weight‑loss drug Foundayo and management says production is ready to scale, supporting near‑term revenue upside from obesity treatments. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: Buy arguments and analyst support: multiple bullish writeups (including a “3 Reasons To Buy” piece and a modest price‑target raise after approval) highlight durable cash flows from GLP‑1 drugs and refreshed upside assumptions. 3 Reasons To Buy Eli Lilly Now Price Target Raised After FDA Approval
• Positive Sentiment: Pipeline diversification: Lilly amended its collaboration with AC Immune to advance next‑generation tau inhibitors toward IND‑enabling studies in 2026, expanding long‑term Alzheimer’s/neurodegeneration exposure beyond metabolic drugs. Eli Lilly Extends AC Immune Tau Pact
• Neutral Sentiment: Investor attention and commentary: Zacks and other outlets note heavy investor interest and that Lilly has lagged recent market gains despite its headline activity — useful context for short‑term volume/volatility. Eli Lilly (LLY) Ascends But Remains Behind Market
• Negative Sentiment: Competitive pricing pressure: Novo Nordisk launched a higher‑dose Wegovy at a significantly lower cash price than Lilly’s Zepbound/Foundayo positioning, creating margin and market‑share risks in the obesity market. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Analyst downgrade / short‑term sell pressure: reports show at least one analyst downgrade that pushed intraday selling and headlines about the stock dipping after the new approval, reflecting investor sensitivity to competition and side‑effect narratives. Trading Down on Analyst Downgrade Stock Dips Following FDA Approval
• Negative Sentiment: Valuation/forecast adjustments: at least one research note trimmed fair‑value assumptions slightly while leaving a high base case, underscoring debates over how much obesity/diabetes upside is already priced in. Obesity & Diabetes Story Reframes Investment Narrative

Eli Lilly and Company Trading Up 2.3%

Shares of Eli Lilly and Company stock opened at $952.24 on Thursday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm has a market capitalization of $899.69 billion, a price-to-earnings ratio of 41.49, a PEG ratio of 1.09 and a beta of 0.51. The firm’s 50 day simple moving average is $987.31 and its two-hundred day simple moving average is $973.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 EPS. Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.